ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
FREMONT, CA - (NewMediaWire) - July 02, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary BioFirst Corporation received a milestone payment of 10M shares of ForSeeCon Eye Corporation’s securities to which the parties impute a value of $6 per share based on an internal valuation1 and a cash payment of $196,000 for its global licensing agreement with ForSeeCon Eye Corporation, which is for the Company's Ophthalmology pipeline, including the medical device Vitargus® (valued at $187M, by third-party valuer) (the "Licensed Products"). ForSeeCon Eye Corporation is a private company registered in the British Virgin Islands. With this payment, the Company has now received aggregate cash payments of $296,000 from ForSeeCon and Oncox ($100,000), one of the Company’s other licensees. In addition to the cash payment, the Company has already received stocks from AiBtl (another licensee) and ForSeeCon, which the company believes are valued at $460M and $60M, respectively.2 The Company expects to receive additional stocks from OncoX that the Company believes is valued at $50M,3 up to $23.7M in cash and royalties of up to $370M from net sales from all three licensees (AiBtl, ForSeeCon, and OncoX), although such net sales cannot be guaranteed.
"This milestone payment marks a significant achievement in the partnership between ABVC and ForSeeCon. It reflects ForSeeCon's confidence in the Licensed Products and its determination to bring the Licensed Products to market if it completes the remaining clinical trials. It also underscores the progress towards the overall project objectives," said Dr. Uttam Patil, ABVC's Chief Executive Officer. He added, "The team is thrilled to receive this milestone payment from its valued partner and expects the remaining $6.8M soon. In addition to the milestone payment, the collaboration between ABVC and ForSeeCon will continue to work on adding more sites for the pivotal study and ramp up the momentum for further development to get Vitargus® commercialized."
"It demonstrates the strength of our collaboration and the dedication of both teams to achieving our shared goals. This milestone represents an important step forward in our project and reaffirms our commitment to delivering innovative solutions in the Ophthalmology industry," said Jerry Chang, CEO of ForSeeCon Eye Corporation. He added, "ForSeeCon is also working on getting the Vitargus Pilot plant facility to upgrade and receive the GMP certification."
Management believes the Company's product pipeline has excellent market potential. According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, at a CAGR of 7.7%, driven partly by the rising geriatric population worldwide.4
For more information about ABVC and its subsidiaries, stay updated on the latest updates or visit https://abvcpharma.com. ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707
About ABVC BioPharma & Its Industry
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct global clinical trials through Phase III.
Forward-Looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
Contact:
Leeds Chow
Email: leedschow@ambrivis.com
[1] This valuation has not been reviewed or verified by a third party.
[2] This valuation has not been reviewed or verified by a third party.
[3] This valuation has not been reviewed or verified by a third party.